Abstract: There are many factors affecting the incidence of glaucoma, and intraocular pressure is still the only controllable factor. Drug therapy is mainly based on topical administration of conventional eye drops. This method has certain shortcomings, including the low bioavailability of the drug, the uncorrect medication of the patient and the low compliance. In recent years, the continuous development of drug delivery system (DDS) has made it possible to successfully solve the above problems. Implantable DDS can be divided into degradable type and non-degradable type, which can keep the effective concentration of the drug in the eye for a long time, and is especially suitable for eye diseases that require long-term treatment. In recent years, a total of 5 new glaucoma drug slow-release devices including bimatoprost SR, ENV515, iDose, OTX-TP, L-PPDS have been put into clinical trials. (Int Rev Ophthalmol, 2021, 45: 285-289)

Key words: glaucoma, sustained-release drug delivery system, intraocular pressure